Ridgetech Inc.
No enriched coverage for $RDGT in the last 7 days.
No SEC Form 4 filings for $RDGT in the last 30 days.
See all $RDGT insider activity →Ridgetech Inc. (RDGT) has been authorized for 360 billion shares following a capital reduction and share subdivision. The company's authorized share capital is now $36.01 million, with 360 billion ordinary shares at $0.0001 par value each. The changes were approved by the Cayman Islands Registrar of Companies and became effective on September 2, 2026.
Ridgetech (RDGT) shareholders approved governance changes and a capital restructuring at their August 25 AGM. This includes a board-authorized reverse stock split between 1-for-20 and 1-for-200 to comply with Nasdaq rules. Shareholders also endorsed a new memorandum, reduced the quorum threshold, and ratified YCM CPA as auditor.
Ridgetech, Inc. (Nasdaq: RDGT) reported fiscal year 2026 results for the year ended March 31, 2026. Revenue rose 10.2% to $132.16 million, driven by a full year of Allright’s online platform after its Feb. 28, 2025 acquisition. Gross profit increased 23.8% to $4.75 million, but net loss was $1.25 million versus net income $10.20 million a year earlier.
Recent RDGT coverage spans corporate actions, insider activity and earnings.
The share subdivision dramatically expands the float, potentially diluting existing shareholders and affecting liquidity.
Potential dilution and share price adjustment; compliance with Nasdaq may stabilize listing.
Wholesale transition and Allright contribution drove revenue growth, but margins remain thin and the company swung to a net loss.
Earnings miss on profitability despite revenue increase; mixed operational outlook.
Recognition of Jiuxin Medicine’s traceability initiative may support Ridgetech’s compliance and operational positioning, but it is not a quantified financial catalyst.
AlphAI scores every news story that mentions RDGT with an AI model for sentiment and relevance, and aggregates insider trades from Ridgetech Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Ridgetech Inc. (RDGT) has been authorized for 360 billion shares following a capital reduction and share subdivision. The company's authorized share capital is now $36.01 million, with 360 billion ordinary shares at $0.0001 par value each. The changes were approved by the Cayman Islands Registrar of Companies and became effective on September 2, 2026.
2 min readRidgetech (RDGT) shareholders approved governance changes and a capital restructuring at their August 25 AGM. This includes a board-authorized reverse stock split between 1-for-20 and 1-for-200 to comply with Nasdaq rules. Shareholders also endorsed a new memorandum, reduced the quorum threshold, and ratified YCM CPA as auditor.
1 min readRidgetech, Inc. (Nasdaq: RDGT) reported fiscal year 2026 results for the year ended March 31, 2026. Revenue rose 10.2% to $132.16 million, driven by a full year of Allright’s online platform after its Feb. 28, 2025 acquisition. Gross profit increased 23.8% to $4.75 million, but net loss was $1.25 million versus net income $10.20 million a year earlier.
6 min readRidgetech Inc. (RDGT) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 Ridgetech, Inc. Reports Fiscal Year 2026 Financial Results HANGZHOU, China, July 31, 2026 /PRNewswire/ -- Ridgetech, Inc. (Nasdaq: RDGT) (“Ridgetech” or the “Company”), a wholesale distributor of pharmaceutical and other healthcare products in China, today announced
2 min readRidgetech, Inc. (Nasdaq: RDGT) said its wholly owned Zhejiang Jiuxin Medicine Co. was elected a vice-president unit of the Hangzhou Qiantang District Biomedical and Cosmetic High-Quality Development Association, to be inaugurated July 28, 2026. The company links the role to Jiuxin’s full-variety drug traceability code scanning in Zhejiang, following an March 2026 inspection by the Zhejiang Medical Products Administration.
3 min readBiotech gainers included Zhengye Biotechnology (ZYBT), up about 1,048% after a Nasdaq bid-price noncompliance notice. Advanced Biomed (ADVB) rose over 70% after withdrawing a planned SEC-registered offering. Neuronetics (STIM) gained after naming a new CFO. Armata Pharmaceuticals (ARMP) advanced on Phase 3 AP-SA02 progress. Other movers: Profusa (PFSA), Ridgetech (RDGT), Turn Therapeutics (TTRX).
6 min readHRT FINANCIAL LP purchased 41,136 shares of Ridgetech Inc. (RDGT) at an average of $1.52 ($1.50–$1.52) across 2 trades over 2026-06-30 to 2026-07-01.
2 min readHRT FINANCIAL LP purchased 19,373 shares of Ridgetech Inc. (RDGT) at $1.61 on 2026-06-11.
2 min readHRT FINANCIAL LP purchased 39,336 shares of Ridgetech Inc. (RDGT) at an average of $1.72 ($1.62–$1.78) across 2 trades over 2026-06-09 to 2026-06-10.
1 min read
